Wegovy vs Mounjaro vs Ozempic: complete 2026 comparison
If you are choosing — or being prescribed — a GLP-1 weight loss medication in 2026, the three names you will see are Wegovy, Mounjaro and Ozempic (with Zepbound as the US weight-loss brand of Mounjaro). This guide compares them honestly, with the trial numbers, the side-effect reality, the cost and supply context, and how to decide which is right for you.
This is not a recommendation for any specific drug. It is a framework for the conversation you should be having with your prescriber, and for the data you should be logging in your GLP-1 tracker to make that conversation worth having.
The 30-second answer
- Ozempic = semaglutide, weekly injection, approved for type 2 diabetes (used off-label for weight loss).
- Wegovy = the same drug as Ozempic (semaglutide), approved and dosed for weight loss.
- Mounjaro = tirzepatide, a dual GIP + GLP-1 agonist, approved for type 2 diabetes (the weight-loss brand is Zepbound).
- On average, tirzepatide produces more weight loss than semaglutide in head-to-head trials.
- Side-effect profile is broadly similar across all three.
Side-by-side comparison table
| | Ozempic (semaglutide) | Wegovy (semaglutide) | Mounjaro / Zepbound (tirzepatide) | | --- | --- | --- | --- | | Drug class | GLP-1 agonist | GLP-1 agonist | Dual GIP + GLP-1 agonist | | Primary approval | Type 2 diabetes | Weight loss | T2D (Mounjaro) / weight loss (Zepbound) | | Average weight loss at ~68 weeks | ~10–12% (T2D trials) | ~15% (STEP) | ~20–22% (SURMOUNT) | | Top dose | 2.0 mg weekly | 2.4 mg weekly | 15 mg weekly | | Typical titration | 0.25 → 0.5 → 1.0 → 2.0 mg | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg | | HbA1c reduction in T2D | ~1.5–1.8% | n/a (weight-loss approved) | ~2.0–2.4% | | Common side effects | Nausea, reflux, constipation, fatigue | Same | Same | | Notable distinct effects | — | — | Some report less reflux, more burping | | Supply (2026) | Generally available | Generally available | Improving but still patchy in some regions | | Typical retail cost (US, 2026) | $$$ | $$$ | $$$ (Zepbound often slightly lower) |
These figures are population averages from published clinical trials — individual response varies widely. The honest comparison is your own data over 12+ weeks in Weight, Symptoms & Notes and Blood Tests.
How they work — the simple version
Semaglutide (Ozempic, Wegovy) mimics GLP-1, a hormone released after meals. It slows gastric emptying, increases satiety, lowers post-meal glucose, and reduces food-related cravings in the brain.
Tirzepatide (Mounjaro, Zepbound) does the same — and also activates the GIP receptor, a second incretin hormone. The dual action is thought to explain why average weight loss is higher.
Neither drug "burns fat". They reduce appetite and improve glucose handling. The weight loss is the result of eating less, more comfortably, for long enough that the body recomposes.
Average results vs your results
Trial averages are useful for setting expectations, not for predicting your outcome. Two people on Wegovy 2.4 mg can lose 5% and 22%. Two people on Mounjaro 10 mg can lose 8% and 25%. The reasons:
- Starting weight and body composition.
- Baseline metabolic health (insulin resistance, thyroid, sleep).
- Protein intake and resistance training.
- Sleep, stress and alcohol.
- Strict vs flexible adherence.
- Genetics — increasingly recognised in GLP-1 response variability.
This is exactly why the how to track GLP-1 progress guide leans on smoothed trends, waist measurements and photos rather than single weigh-ins.
Side effects — what to expect
All three drugs share the same dominant side-effect profile:
- Nausea (most common, usually peaks after dose escalations).
- Reflux and burping.
- Constipation.
- Fatigue, especially in the 24–72 hours after injection.
- Reduced appetite (intended) and occasional food aversions.
- Less commonly: gallbladder issues, pancreatitis, severe vomiting.
The full breakdown — and how to log them — is in the Ozempic side effects guide.
There is no clear evidence that one drug is dramatically better tolerated than the others on average, although individuals report large differences. The only way to know what you tolerate is structured logging in Symptoms & Notes for 8–12 weeks per drug.
Cost, availability and access in 2026
- Pricing varies hugely by country and insurance.
- Supply has improved since the 2023–2024 shortages but is still uneven by region and dose.
- Some pharmacies and telehealth services offer Wegovy and Zepbound at lower out-of-pocket cost than retail.
- Compounded semaglutide is widely available but quality, sterility and dosing accuracy vary — use only via a licensed provider you trust.
How to choose
A reasonable framework, in this order:
- What can your prescriber actually prescribe and your insurance actually cover? This eliminates half the debate.
- What is your goal? Modest loss + metabolic improvement → either drug is fine. Large loss (≥15%) → tirzepatide has the trial edge.
- What do you tolerate? Past experience with one drug often predicts tolerance of the other.
- What is your timeframe? A 12-month plan and a 5-year plan have different drug choices.
- Is maintenance the goal? Plan the taper before you start.
Common mistakes when choosing
- Picking the drug with the best headline number without considering side effects and cost.
- Switching at week 4 — too soon to compare.
- Using compounded versions to save money without understanding the quality risks.
- Starting without a baseline in Weight and Blood Tests.
- No exit plan — every GLP-1 should have a taper or maintenance plan before week one. See coming off Ozempic.
Real-world scenarios
A. Type 2 diabetes, modest weight goal, Ozempic prescribed and tolerated well. No reason to switch.
B. No diabetes, BMI 35, goal is 20%+ loss. Tirzepatide (Zepbound) is a reasonable first-line conversation.
C. On Wegovy 2.4 mg, plateau 10+ weeks. Read the plateau guide first; a switch to tirzepatide is a reasonable next step.
D. Intolerable reflux on Ozempic. Some people tolerate tirzepatide better; others do not. Try with structured logging.
E. Reached goal weight on Mounjaro. Discuss tapering to a maintenance dose rather than stopping.
Doctor discussion points
- Goal: total loss, metabolic control, both.
- Past GLP-1 history (drug, dose, tolerance, results).
- Current weight trend from Weight.
- Symptoms from Symptoms & Notes.
- HbA1c, lipids, ALT/AST, kidney markers from Blood Tests.
- Cost and insurance reality.
- Plan for tapering / maintenance.
The Doctor Appointment handout pre-fills these from your logs.
FAQs
Is Mounjaro better than Wegovy?
On average, tirzepatide produces more weight loss than semaglutide in trials. For an individual, the better drug is the one that is accessible, tolerable and sustainable.
Are Ozempic and Wegovy the same drug?
Yes — both are semaglutide. Wegovy is the brand and dosing approved for weight loss; Ozempic is approved for type 2 diabetes and used off-label.
What about Zepbound vs Mounjaro?
Same drug (tirzepatide). Zepbound is the brand approved for weight loss; Mounjaro is the brand approved for type 2 diabetes.
Can I switch from one to the other?
Yes, under medical supervision. Expect a fresh titration period with the new drug.
How long should I stay on a GLP-1?
There is no fixed answer. Many people stay on long-term at a maintenance dose; others taper. The coming off Ozempic guide covers the decision.
Will any of these drugs work without diet and exercise?
Yes, somewhat — but lean mass, energy and long-term maintenance all suffer. Protein, sleep and resistance training are non-negotiable for good outcomes.
Who should not start GLP-1 medication
GLP-1 receptor agonists like Ozempic, Wegovy and Mounjaro are prescription medications and are not appropriate for everyone. They are generally avoided in people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disease such as gastroparesis, active pancreatitis, and during pregnancy or breastfeeding. If you take insulin or sulfonylureas you may need dose adjustments to avoid low blood sugar. None of the information here is medical advice — always talk to your doctor before starting, changing or stopping any GLP-1 medication.
How BodySynk supports your GLP-1 treatment day to day
A GLP-1 medication only works as well as the routine around it. BodySynk is built to be that routine — a calm, private health memory that quietly captures what changes from week to week so you and your doctor can see the full picture, not a single weigh-in.
- Injections: log every dose, weekday and time in Obesity Drugs — see exactly when you escalated and how your body responded.
- Weight: Weight shows a smoothed 7-day trend that ignores daily noise from salt, sleep and cycle.
- Body measurements: waist, hip, chest and thigh entries reveal recomposition the scale misses.
- Progress photos: private side-by-side comparisons in Cosmetic & Photos make six-month changes obvious.
- Symptoms & side effects: Symptoms & Notes timestamps nausea, reflux, fatigue, mood and appetite so you can spot dose-day patterns.
- Bloodwork: upload labs to Blood Tests and watch HbA1c, lipids, ALT and kidney markers move across panels.
- Other medications: track interactions and adherence in Medications.
- Nutrition: scan or log meals in Nutrition without calorie shaming — the goal is protein, fibre and hydration patterns, not a number.
- Supplements: keep electrolytes, fibre, B12 and creatine in Supplements.
- Doctor visits: generate a one-page handout from Doctor Appointment covering dose, trend, side effects and questions.
- The story: every entry flows into BodyStory — a single chronological view of your treatment.
Pair it with the pillar guide to the best GLP-1 tracker to set the whole system up in under ten minutes.